Intracellular bacteria recognition contributes to maximal interleukin (IL)-12 production by IL-10-deficient macrophages

von Naruse, H, Hisamatsu, T, Yamauchi, Y, Chang, J E, Matsuoka, K, Kitazume, M T, Arai, K, Ando, S, Kanai, T, Kamada, N, Hibi, T
Veröffentlicht 2011

Capecitabine and oxaliplatin in combination as first or second-line therapy for metastatic breast cancer: A Wisconsin Oncology Network trial

von Njiaju, U.O., Tevaarwerk, A.J., Kim, K., Chang, J.E., Hansen, R.M., Champeny, T.L., Traynor, A.M., Meadows, S., Van Ummersen, L., Powers, K., Stewart, J.A.
Veröffentlicht 2012

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

von Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N.S., Longo, W.L., Kahl, B.S.
Veröffentlicht in Clin Lymphoma Myeloma Leuk (2017)

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

von Chang, J. E., Peterson, C., Choi, S., Eickhoff, J. C., Kim, K., Yang, D. T., Gilbert, L. A., Rogers, E. S., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N. S., Longo, W. L., Kahl, B. S.
Veröffentlicht 2011